These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

520 related items for PubMed ID: 19166708

  • 1. Role of antiplatelet therapy across the spectrum of patients with coronary artery disease.
    Bhatt DL.
    Am J Cardiol; 2009 Feb 02; 103(3 Suppl):11A-19A. PubMed ID: 19166708
    [Abstract] [Full Text] [Related]

  • 2. Indications for dual antiplatelet therapy with aspirin and clopidogrel: evidence-based recommendations for use.
    Reaume KT, Regal RE, Dorsch MP.
    Ann Pharmacother; 2008 Apr 02; 42(4):550-7. PubMed ID: 18319394
    [Abstract] [Full Text] [Related]

  • 3. An appraisal of dual antiplatelet therapy with clopidogrel and aspirin for prevention of cardiovascular events.
    Terpening C.
    J Am Board Fam Med; 2009 Apr 02; 22(1):51-6. PubMed ID: 19124633
    [Abstract] [Full Text] [Related]

  • 4. Percutaneous coronary intervention: assessing coronary vascular risk associated with bare-metal and drug-eluting stents.
    Spinler SA.
    Am J Manag Care; 2009 Mar 02; 15(2 Suppl):S42-7. PubMed ID: 19355808
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Current antiplatelet therapies: benefits and limitations.
    Angiolillo DJ, Guzman LA, Bass TA.
    Am Heart J; 2008 Aug 02; 156(2 Suppl):S3-9. PubMed ID: 18657680
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Should dual antiplatelet therapy after drug-eluting stents be continued for more than 1 year?: Dual antiplatelet therapy after drug-eluting stents should be continued for more than one year and preferably indefinitely.
    Chhatriwalla AK, Bhatt DL.
    Circ Cardiovasc Interv; 2008 Dec 02; 1(3):217-25. PubMed ID: 20031681
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Optimizing long-term dual aspirin/clopidogrel therapy in acute coronary syndromes: when does the risk outweigh the benefit?
    Collet JP, Montalescot G.
    Int J Cardiol; 2009 Mar 20; 133(1):8-17. PubMed ID: 19187982
    [Abstract] [Full Text] [Related]

  • 18. Prasugrel: newest antiplatelet agent and its emerging role in management of acute coronary syndrome and percutaneous coronary intervention.
    Robinson A, Das K, Koshy SK, Das P.
    Future Cardiol; 2009 May 20; 5(3):237-46. PubMed ID: 19450050
    [Abstract] [Full Text] [Related]

  • 19. Effectiveness of two-year clopidogrel + aspirin in abolishing the risk of very late thrombosis after drug-eluting stent implantation (from the TYCOON [two-year ClOpidOgrel need] study).
    Tanzilli G, Greco C, Pelliccia F, Pasceri V, Barillà F, Paravati V, Pannitteri G, Gaudio C, Mangieri E.
    Am J Cardiol; 2009 Nov 15; 104(10):1357-61. PubMed ID: 19892050
    [Abstract] [Full Text] [Related]

  • 20. Prior antiplatelet use and cardiovascular outcomes in patients presenting with acute coronary syndromes.
    El-Menyar A, AlHabib KF, Al-Motarreb A, Hersi A, Al Faleh H, Asaad N, Al Saif S, Almahmeed W, Sulaiman K, Amin H, Al-Lawati J, Alsheikh-Ali AA, AlQahtani A, Al-Sagheer NQ, Singh R, Al Suwaidi J.
    Am J Cardiovasc Drugs; 2012 Apr 01; 12(2):127-35. PubMed ID: 22257172
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 26.